These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 232318)

  • 1. Prostacyclin analogs: antiaggregatory potency and enhancement of cAMP levels in human platelet rich plasma.
    Dembinska-Kiec A; Rücker W; Schönhöfer PS; Gandolfi C
    Thromb Haemost; 1979 Dec; 42(4):1340-3. PubMed ID: 232318
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of human platelet function by prostacyclin and thromboxane A2.
    Gorman RR
    Fed Proc; 1979 Jan; 38(1):83-8. PubMed ID: 215465
    [No Abstract]   [Full Text] [Related]  

  • 3. Reciprocal regulation of human platelet cAMP levels by thromboxane A2 and prostacyclin.
    Gorman RR; Fitzpatrick FA; Miller OV
    Adv Cyclic Nucleotide Res; 1978; 9():597-609. PubMed ID: 208399
    [No Abstract]   [Full Text] [Related]  

  • 4. Modified sensitivity of diabetic platelets to prostacyclin.
    Bonne C; Romquin N; Regnault F
    Bibl Anat; 1979; (18):98-103. PubMed ID: 227357
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition and subsequent enhancement of platelet responsiveness by prostacyclin in the rabbit. Relationship to platelet adenosine 3',5'-cyclic monophosphate.
    Vanderwel M; Haslam RJ
    J Clin Invest; 1985 Jul; 76(1):233-40. PubMed ID: 2991338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is prostacyclin a physiologically important circulating anti-platelet agent?
    Steer ML; MacIntyre DE; Levine L; Salzman EW
    Nature; 1980 Jan; 283(5743):194-5. PubMed ID: 6243178
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic AMP.
    Weithmann KU
    Gen Pharmacol; 1983; 14(1):161-2. PubMed ID: 6298055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel prostaglandin endoperoxide analogs having prostacyclin-like actions on platelets from human and horse but not from rat and rabbit.
    Wilson NH; Armstrong RA; Jones RL
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():491-5. PubMed ID: 2821762
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of adenosine 3':5'-monophosphate and platelet aggregation on thromboxane biosynthesis in human platelets.
    Lindgren JA; Claesson HE; Kindahl H; Hammarström S
    FEBS Lett; 1979 Feb; 98(2):247-50. PubMed ID: 217731
    [No Abstract]   [Full Text] [Related]  

  • 11. The increased sensitivity of platelets to prostacyclin in marathon runners.
    Dix CJ; Hassall DG; Bruckdorfer KR
    Thromb Haemost; 1984 Jul; 51(3):385-7. PubMed ID: 6093280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of cyclic AMP metabolism in human platelets. Sequential activation of adenylate cyclase and cyclic AMP phosphodiesterase by prostaglandins.
    Alvarez R; Taylor A; Fazzari JJ; Jacobs JR
    Mol Pharmacol; 1981 Sep; 20(2):302-9. PubMed ID: 6272089
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline.
    Manrique RV; Manrique V
    Angiology; 1987 Feb; 38(2 Pt 1):101-8. PubMed ID: 3030162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacology of prostacyclin].
    Imai S
    Kokyu To Junkan; 1985 Jul; 33(7):845-9. PubMed ID: 2997894
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 16. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
    Schrör K; Löbel P; Steinhagen-Thiessen E
    Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug stimulated prostacyclin release.
    Weithmann KU
    Ric Clin Lab; 1981; 11 Suppl 1():209-14. PubMed ID: 6324324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of PGI2 and di-butyryl cyclic-AMP on platelets exposed to shear stress.
    Hardwick RA; Hellums JD; Peterson DM; Moake J; Olson J
    Trans Am Soc Artif Intern Organs; 1981; 27():192-6. PubMed ID: 6277071
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin.
    Siegl AM; Daly JW; Smith JB
    Mol Pharmacol; 1982 May; 21(3):680-7. PubMed ID: 6287202
    [No Abstract]   [Full Text] [Related]  

  • 20. Refractoriness of diabetic platelets to inhibitory prostaglandins.
    Lagarde M; Berciaud P; Burtin M; Dechavanne M
    Prostaglandins Med; 1981 Oct; 7(4):341-7. PubMed ID: 6273957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.